Form 4: Personalis Director Woodrow A. Myers Jr. Acquires 50,000 Stock Options

Director Woodrow A. Myers Jr. of Personalis, Inc. was granted 50,000 stock options on May 17, 2024.

Summary

• On May 17, 2024, Woodrow A. Myers Jr., a director of Personalis, Inc., acquired 50,000 stock options.
• The exercise price of these options is $1.40.
• The options vest on the earlier of the one-year anniversary of the grant date or the day prior to the company's next annual meeting of stockholders after the grant date, contingent upon continuous service.
• In the event of a Change in Control, the options will vest immediately.
• The options expire on May 17, 2034.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and generally viewed as a positive incentive for management.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service and commitment to the company.

Future Outlook

The vesting of the options is contingent upon continued service and may be accelerated by a Change in Control.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the biotech industry.
• Companies like Illumina, Inc. and Exact Sciences Corp also use stock options to incentivize their directors and officers.
• The vesting schedule and exercise price are generally in line with industry practices for similar-sized companies.

Stakeholder Impact

• The stock option grant could potentially increase shareholder value if the director's performance leads to company growth.
• The grant incentivizes the director to act in the best interests of the company and its shareholders.

Key Dates